Impact of continued administration of tolvaptan on cirrhotic patients with ascites
Abstract Background The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We investigated the outcome of long-term treatment. Methods This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63 years) were enroll...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-12-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40360-018-0277-3 |